Which generation of targeted drug is Amivantamab?

Amivantamab (Amivantamab) is a fourth-generation targeted drug. Fourth-generation targeted drugs represent the latest innovations in cancer treatment and are developed to overcome some of the limitations of previous generation drugs and provide more highly specific and effective treatment options.

The main characteristics of the fourth generation of targeted drugs include the following aspects:

1.Higher specificity: The fourth generation of targeted drugs can more accurately identify specific molecular targets on cancer cells, thereby reducing interference with normal cells. This reduces the risk of adverse reactions and improves the safety of the treatment.

2.Action on multiple targets: Unlike previous generations of targeted drugs, fourth-generation targeted drugs are usually able to interfere with multiple key molecular targets at the same time to more comprehensively interfere with the growth and spread of cancer cells. This helps reduce tumor cells escaping treatment.

3.Overcoming drug resistance: The design of the fourth generation of targeted drugs can help overcome the drug resistance problems faced by previous generations of drugs. They can affect cancer cells in different ways, reducing the risk of developing drug resistance.

Evantumumab is a typical fourth-generation targeted drug. Its targeting mechanism includes acting on two key molecular targets: EGFR (epidermal growth factor receptor) and MET (muscle-specific casein kinase). This drug is widely studied for the treatment of specific subtypes of non-small cell lung cancer (NSCLC), such as EGFR gene mutations and METex14 deletions, providing new treatment options for these patients.

Evantuzumab is not yet available in China, so patients cannot purchase it domestically and need to purchase it through foreign channels. There are only European versions of original drugs available abroad, and the price is relatively high, around 20,000 yuan.